These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 28103901)

  • 41. Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival.
    Kang J; Huang G; Ma L; Tong Y; Shahapal A; Chen P; Shen J
    Elife; 2024 Jun; 12():. PubMed ID: 38856715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Wnk kinases are positive regulators of canonical Wnt/β-catenin signalling.
    Serysheva E; Berhane H; Grumolato L; Demir K; Balmer S; Bodak M; Boutros M; Aaronson S; Mlodzik M; Jenny A
    EMBO Rep; 2013 Aug; 14(8):718-25. PubMed ID: 23797875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LRRK2 and idiopathic Parkinson's disease.
    Rocha EM; Keeney MT; Di Maio R; De Miranda BR; Greenamyre JT
    Trends Neurosci; 2022 Mar; 45(3):224-236. PubMed ID: 34991886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.
    Gonzalez-Cano L; Menzl I; Tisserand J; Nicklas S; Schwamborn JC
    Mol Neurobiol; 2018 Apr; 55(4):3490-3498. PubMed ID: 28508149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights.
    Skelton PD; Tokars V; Parisiadou L
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
    Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
    Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional and behavioral consequences of Parkinson's disease-associated
    Benson DL; Matikainen-Ankney BA; Hussein A; Huntley GW
    Biochem Soc Trans; 2018 Dec; 46(6):1697-1705. PubMed ID: 30514770
    [No Abstract]   [Full Text] [Related]  

  • 52. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular effects mediated by pathogenic LRRK2: homing in on Rab-mediated processes.
    Madero-Pérez J; Fdez E; Fernández B; Lara Ordóñez AJ; Blanca Ramírez M; Romo Lozano M; Rivero-Ríos P; Hilfiker S
    Biochem Soc Trans; 2017 Feb; 45(1):147-154. PubMed ID: 28202668
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LRRK2 activation in idiopathic Parkinson's disease.
    Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
    Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation.
    Prabhudesai S; Bensabeur FZ; Abdullah R; Basak I; Baez S; Alves G; Holtzman NG; Larsen JP; Møller SG
    J Neurosci Res; 2016 Aug; 94(8):717-35. PubMed ID: 27265751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
    Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.